<DOC>
	<DOC>NCT02670785</DOC>
	<brief_summary>This study will access the safety and efficacy of three doses of estradiol vaginal capsules in postmenopausal women with vulvovaginal atrophy.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Clinical diagnosis of vulvovaginal atrophy due to post menopause Age ≥ 40 years or if bilateral oophorectomy ≥ 35 years Moderate to severe vaginal dryness Normal breast exam; if &gt; 40 years Vaginal pH &gt; 5.0 &lt; 5% superficial cells on vaginal wall cytology smear Known hypersensitivity to estrogen and/or progestin therapy Known or suspected premalignant or malignant disease Undiagnosed abnormal genital bleeding A history of or treatment for significant cardiovascular disease, congestive heart failure, or stroke Active or known protein C, protein S, or antithrombin deficient, or other known thrombophilic disorders or thromboembolic events Increased frequency/severity headaches with estrogen therapy Smokes ≥ 15 cigarettes/day</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>